# Duodenal ReCET for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease

> **NCT07390422** · NA · NOT_YET_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 40 (estimated)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Syndrome (MetS)

## Interventions

- **PROCEDURE:** ReCET treatment

## Key facts

- **NCT ID:** NCT07390422
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2031-03-31
- **Final completion:** 2033-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07390422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07390422, "Duodenal ReCET for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07390422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*